Jeffrey C. Davis, MD

• American Board of Orthopaedic Surgery, Board Certified

“An Active Comparator-Controlled, Parallel-Group, 1-Year, Double-Blind Study, Conducted Under In-House Blinding Conditions, to Assess the Safety and Efficacy of MK-0966 Versus Diclofenac Sodium in Patients With Osteoarthritis of the Knee of Hip”, Merck & Co., Inc., 1996

“A Double-Blind Comparison of the Efficacy and Safety of Extended Outpatient Treatment with Subcutaneous Normiflo^TM VS. Placebo for the Prevention of Venous Thromboembolism in Patients After Hip or Knee Replacement Surgery” Wyeth-Ayest, 1996.

“Relative Analgesic Efficacy and Safety of Oxycodone HCL 1.0 mg/Ibuprofen 400 mg, Oxycodone HCL 5 mg/Ibuprofen 400 mg, and Ibuprofen 400 mg Alone in Post Orthopedic Surgical Pain”, Forest Laboratories, 1997.

“A Placebo and Active Comparator-Controlled, Parallel-Group, 6 Week, Double Blind Study, Conducted Under In-House Blinding Conditions, to Assess the Safety and Efficacy of MK-0966 Versus Ibuprofen in Patients With Osteoarthritis of the Knee of Hip”, Merck & Co., 1997.

“A Phase III Study of the Effect of MK-0966 in the Treatment of Post Orthopedic Surgical Pain”, Merck, 1997.

“Double-Blind, Placebo Controlled, Parallel Group Comparison of the Efficacy and Safety of Morphelan TM, MS Contin”, and “Placebo with an Open label Extension in the Treatment of Osteoarthritis of the Knee and/or Hip”, Targon Corporation, 1998.

“A Randomized, Double-Blind, Efficacy and Safety Study of Oxycontin@ Tablets Administered in a Step-Down Regimen Q12H Compared to OxyContin@ Tablets in a Constant Dose Regiment Q12H after Outpatient Surgery”, Purdue Pharma. L.P., Merck, 1999.

“A Randomized, Double-Blind Comparison of the Efficacy and Safety of Hylan GF- 20 and Saline in Patients with Osteoarthritis of the Knee”, Wyeth-Ayerst, 1999.

“Double-Blind, Placebo Controlled, Dose Ranging Comparison of the Efficacy and Safety of Controlled Release Oxymorphone (Nurnorphan CR), Controlled Release Oxycodone (OxyContin~ and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip”, Endo Pharmaceuticals, 1999.

“Relative Analgesic Efficacy and Safety of Oxycodone HCL 10 mg/Ibuprofen 400 mg, Oxycodone 5 mg/Ibuprofen in Patients with Osteoarthritis of the Knee or Hip”, Merck & Co., Inc., 1997.

“A Multicenter, Open Label Extension Study to Evaluate the Long-Term Safety and Effectiveness of Numorphan CR in Patients with Chronic Pain”, Endo Pharmaceuticals, 1999.

“A Double-Blind, Placebo Controlled, Parallel Group, Dose Ranging Comparison of the Efficacy, Upload Dose Sparing Effects, and Safety of Controlled Release Oxymorphone (Numorphan cr~ and Placebo in Patients with Post-Surgical Pain Following Total Knee Arthroplasty”, Endo Pharmaceuticals, 1999.

“A Randomized, Placebo Controlled, Parallel Group, Double-Blind Study to Evaluate the Safety and Efficacy and Rofecoxib 12.5 mg, Rofecoxib 25 mg, and Celcoxib 200 mg in Patients With Osteoarthritis of the Knee or Hip”, Merck, 200.

“A Randomized, Multicenter, Multi-Dose, Double-Blind, Double-Dummy, Parallel Group Study Comparing the Efficacy and Safety of Sustained-Release Oxycodone (Oxycodone SR) to Placebo in the Treatment of Pain Associated with Osteoarthritis”, Roxane Laboratories, 2000.

“A Randomized Placebo, and Active Comparator Controlled, Parallel Group Study of MK-0663 120 mg and NAPRELAN^TM in the Treatment of Post Orthopedic Surgical Pain”, Merck, 2000.

“A Placebo Controlled, Parallel Group, 4-Week Trial Conducted Uner Double-Blind Conditions to Assess the Efficacy and Safety of Rofecxib in Patients with Chronic Low Back Pain”, Merck, 2000.

“A Double-Blind, Placebo, Controlled Single Dose Evaluation of the Safety and Efficacy of Hydromorphone Hydrochloride Controlled-Release 24 mg Capsules in Acute Post-Operative Pain”, Purdue Pharma, 2000.

“Clinical Protocol for a Double-Blind, Placebo Controlled, Comparison, of the Narcotic Sparing Activities of Valdecoxib 20 mg, Valdecoxib 40 mg, and Placebo in Post-Orthopedic Surgical Patients”, Searle, 2000.

“Double-Blind, Randomized, Dose-Titration, Parallel-Group Comparison of the Efficacy and Safety of Extended Release Tramoadon (Tramadol ER) and Placebo in the Treatment of Osteoarthritis of the Knee”, Biovail Laboratories, Incorporated, 2000.

“Open Label Assessment of the Safety and Effectiveness of Extended Release Tramadol (Tramadol ER) in the Treatment of Chronic Non-Malignant Pain”, Biovail Laboratories, Incorporated, 2000.

“A Randomized, Double-Blind, Placebo Controlled, Parallel Group Evaluation of the Impact of OxyContin (Controlled-Release Oxycodone) vs. Usual Care (Oxycodone {Immediate/Release}/APAP) on Rehabilitation Related Health Outcomes Following Unilateral Total Knee Arthroplasty”, Purdue Pharma, 2001.

“A Multicenter, Open-Label, Multidose, 52-Week Study Designated to Assess the Safety of Propiram Fumarate (Dirame~ in the Treatment of Moderate to Severe Non-Malignant Chronic Pain”, Shire Pharmaceutical Development Inc., 2001.

“A 12 Week, Randomized, Double-Blind, Placebo Controlled, Multi-Center, Parallel Group Study to Investigate the Efficacy and Safety of ML3000 200 mg BID in Patients With Osteoarthritis (OA) of the Knee”, Forest Laboratories, 2001.

“A Single Dose Sequential Two Cohort (Open-Label Sequential Groups/Double-Blind Placebo-Controlled Parallel-Groups) Trial Designed to Evaluated the Efficacy and Safety of a Single Dose of 15, 30, 45 mg Extended-Release Hydrocodone (HCD) in Postoperative Orthopedic Patients”, Purdue Pharma 2001.

“A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Comparator (Controlled Release Oxycodone), Placebo controlled, Parallel Group Trial Assessing the Analgesic Effect of COX189 in the Treatment of Post-Surgical Pain Following Total Knee of Hip Arthroplasty”, Novartis, 2001.

“A Dose-Ranging and Arthrocentesis-Controlled Study of the Safety and Efficacy of Intra-Articular ORTHOVISC Sodium Hyaluronate Injections in Providing Symptomatic Relief of Osteoarthritis of the Knee”, Anika Therapeutics, 2001.

“A Phase III, Randomized, Multicenter, Parallel Group, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Diclofenac Potassium Softgel 25 mg or 50 mg in the Treatment of Arthroscopic Knee Surgery pain”, aaiResearch Pharmaceutical, 2007.

“A Study of the Safety of a Repeat Series of Injections of Intra-Articular ORTHOVISC Sodium Hyaluronate in Patients with Osteoarthritis of the Knee”, Anika Therapeutics, 2002.

“A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Comparison of the Safety and Efficacy of Dlrarne Propiram Fumarat (50 mg, 100 mg, and 150 mg), Oxycodone (5mg), and Placebo in the Treatment of Moderate to Severe Pain After Total Hip Replacement Surgery”, Shire Pharmaceutical Development Inc., 2002.

“A 4-Week, Randomized, Double-Blind, Placebo and Positive Controlled, Parallel Group Multicenter Study of SD-6010 in Subjects with Symptomatic Osteoarthritis of the Knee (A6171009)”, Pfizer Inc., 2004.

“A Randomized, Double-Blind, Placebo Controlled, Phase II Exploratory Study to Evaluate the Analgesic Efficacy and Tolerability of a Single Intra-Articular Injection of ALGRX 4975 in Subjects with Painful Osteoarthritis of the Knee”, AlgoRx Pharmaceuticals, 2004.

“A Multicenter, Parallel, Double-Blind, Blinded Evaluator, Randomized Comparison of the Efficacy and Safety of an alternate Viscosupplement (AVSbeta) to Depo-Medrol (Methylpednisolone acetate) in Patients with Symptomatic Osteoarthritis of the Knee”, Genzyme Corporation, 2004.

“A Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Neramexane in the Treatment of Patients with Osteoarthritis of the Knee”, Forest Research Institute, 2005.

“Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Knee Replacement: ODIXA-KNEE a Randomized, Controlled, Double-Blind, Double-Dummy Phase lib Dose Ranging Trial”, Bayer Pharmaceuticals, Inc., 2005.

“Multi-Center, Double-Blind, Randomized, Placebo Controlled, Multiple Dose Study of the Analgesic Efficacy and Safety of Acetaminophen Injections 1 G vs Placebo for Pain Following Primary Unilateral Total Hip Replacement”, Bristol-Myers Squibb, Inc., 2004.

“Comparison of the Safety and Efficacy of Patient Controlled Analgesia Delivered by HCl Transdermal System Versus Morphine IV Pump for Pain Management after Primary Unilateral Total Hip Replacement”, Pharmanet, Inc., 2004.

“A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Aquavan Injection Versus Midazolam HCl for Sedation in Patients Undergoing Minor Surgical Procedures” Guilford Pharmaceuticals, Inc., 2005.

“A Phase II Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of Oral Factor XA Inhibitor BMS-562247 in Subjects Undergoing Elective Total Replacement Surgery” CV 185-010, 2005.

“A Randomized, Placebo Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects after Total Knee Arthroplasty”, 4975-2-010-1, 2005.

“A Multi-Center, Randomized, Double-Blind Placebo Controlled, Parallel Design, 2-arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement Surgery”, 11694, 2005.

“RECORD 1 Study: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, Controlled Double-Blind, Randomized Study of BAY 59-7939 in Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement”, Bayer Corporation, Inc., 2005.

“RECORD 2 Study: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, Controlled Double-Blind, Randomized Study of BAY 59-7939 in Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement”, Bayer Corporation, Inc., 2005.

“IV Acetaminophen: Efficacy of a Single Dose for Postoperative Pain After Hip Arthroplasty: Subset Data Analysis of 2 Unpublished Randomized Clinical Trials”, American Journal of Therapeutics, 2014.

• Alabama Medical Services Board Chairman   
• Ascension St. Vincent’s Surgical Peer Review
• Ascension St. Vincent’s Credential Committee
• Ascension St. Vincent’s Orthopedic Department Vice-Chair
• Ascension St. Vincent’s Medical Executive Committee
• Board Member – Birmingham Surgery Center